Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — Investor Presentation (September 2026)
29 slides from Jasper Therapeutics's investor presentation, September 2026
Slide 1: Corporate Presentation September 2026
Corporate Presentation September 2026 1
Slide 2: Safe Harbor Statements
Safe Harbor Statements Forward-Looking Statements Certain statements contained in this presentation are or may be considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictl
Slide 3: Overview of the Merger Transaction and Financing
Overview of the Merger Transaction and Financing Merger creates a combined company with deep expertise in antibody drug development and immunologically- driven disorders Merger • On July 16, 2026, Jasper Therapeutics, Inc. (NASDAQ: JSPR) entered into a merger agreement with Kira Pharmaceuticals wher
Slide 4: The Combined Company Plans to Deliver Innovative Therapeutics in Multiple Immune-Driven Disorders
The Combined Company Plans to Deliver Innovative Therapeutics in Multiple Immune-Driven Disorders Significant Global • Large, addressable markets across complement, mast-cell and B-cell mediated disorders1 Opportunity • Phase 2/3 ready in PNH, Phase 2 ongoing in renal disorders Vensobafusp alfa • In
Slide 5: Jasper Executive Team
Jasper Executive Team Experienced drug developers focused on driving value Greg Keenan, MD Chief Medical Officer Rheumatologist, antibody drug developer & former CMO at publicly traded biotechs Jeet Mahal Chief Executive Officer Biotech executive and Board member with 30+ years of experience in deve
Slide 6: Innovative Pipeline Targeting High Value Immunology Targets
Innovative Pipeline Targeting High Value Immunology Targets Mechanism of Indication IND Phase 1 Phase 2 Phase 3 Expected Upcoming Milestones Action Q4 ‘26: Interim data (Stage 1) IgAN, C3G, FSGS Phase 2 Basket Trial Q2 ‘27: Updated data (Stage 1) Anti-C5 mAb + Vensobafusp Factor H Q2 ‘27: Interim da
Slide 7: Vensobafusp alfa (KP104)
Vensobafusp alfa (KP104) Anti-C5 mAb + Factor H Bifunctional Biologic
Slide 8: Vensobafusp alfa: Phase 2/3 Ready, Potential Best-in-Class Complement Inhibitor
Vensobafusp alfa: Phase 2/3 Ready, Potential Best-in-Class Complement Inhibitor Vensobafusp Dual Mechanism of Action: • Simultaneous blockade of the alternative and terminal pathways – Phase 2/3-ready addressing both upstream activation and downstream lytic damage • Phase 2 PNH study complete with 2
Slide 9: Vensobafusp alfa: Dual Mechanism of Action for Increased Potency and Rapid Onset
Vensobafusp alfa: Dual Mechanism of Action for Increased Potency and Rapid Onset Vensobafusp alfa: Dual-targeting of Terminal (C5) PROXIMAL (ALTERNATIVE) Iptacopan and Alternative (Factor H) Pathways Factor B inhibitor • Unique C5- and C5b-binding epitope preventing MAC formation and concentrates dr
Slide 10: Vensobafusp alfa: Favorable Efficacy Profile in PNH Patients at 48 Weeks
Vensobafusp alfa: Favorable Efficacy Profile in PNH Patients at 48 Weeks Rapid normalization of LDH support longer term clinical PNH: Phase 2 results (48 weeks) benefit correlation of thrombosis reduction 100% Hgb ≥2g/dl increase from baseline 94% of patients with LDH 6.6 g/dL Hgb increase from base
Slide 11: Vensobafusp alfa: Dual Inhibition Drives Durable Hgb Improvement
Vensobafusp alfa: Dual Inhibition Drives Durable Hgb Improvement Hgb Normalization in 89% of Patients at 2 Years Sustained Hgb Improvement Reflects Controls of Both IVH and EVH % Patients with Hgb Normalization 82.4% 77.5% 46.4% 20% Vensobafusp Iptacopan Pegcetacoplan Eculizumab 2-year 2-year 48 wee
Slide 12: Vensobafusp alfa: Basket Study to Explore Rare Renal Indications
Vensobafusp alfa: Basket Study to Explore Rare Renal Indications Multiple Opportunities to Achieve Rapid POC Opportunity to demonstrate vensobafusp’s best-in-class potential and differentiated profile in renal indications vs. other complement inhibitors IgAN • IgAN pathogenesis involves both alterna
Slide 13: Vensobafusp alfa: Ongoing Phase 2 Renal Basket Study
Vensobafusp alfa: Ongoing Phase 2 Renal Basket Study Designed to Evaluate Safety, PK/PD and Efficacy in Multiple Renal Indications Stage 1 Stage 2 • Assess the safety, tolerability and initial • Protocol designed to easily add new renal efficacy in IgAN disease cohorts at existing clinical sites • 3
Slide 14: Vensobafusp alfa: Multiple Indication Expansion Opportunities
Vensobafusp alfa: Multiple Indication Expansion Opportunities Across Hematology, Renal and Neurology Disease Areas Indication Opportunities Estimated Market Opportunity: Paroxysmal Nocturnal Hemoglobinuria (PNH) – Phase 2 Complete Hematology PNH1: 28K patients Complement-Mediated Thrombotic Microang
Slide 15: Briquilimab
Briquilimab Potential Best-in-Class Anti-KIT Antibody
Slide 16: Briquilimab: Broad Therapeutic Potential Across Transplant & Immunology
Briquilimab: Broad Therapeutic Potential Across Transplant & Immunology Update on SCID program in Q4'26 & regulatory feedback expected in Q1'27 • Briquilimab is designed to directly block SCF from binding to KIT (CD117) with high affinity and avidity Briquilimab • Aglycoslyated IgG1 antibody directl
Slide 17: Briquilimab: A Differentiated Program in Transplant & Allergic Disorders
Briquilimab: A Differentiated Program in Transplant & Allergic Disorders Open-Label Open-Label Extension Extension SCID, Fanconi, Sickle Cell and CSU: N = 87 CIndU: N = 27 AML / MDS: N = ~40 H1-AH1 failed H1-AH failed (ColdU and SD) • Positive, long-term data supporting • Deep disease control with ∆
Slide 18: Briquilimab: Potential US Licensing Pathway & PRV Opportunity for SCID
Briquilimab: Potential US Licensing Pathway & PRV Opportunity for SCID SCID and Fanconi anemia are difficult to treat ultra-orphan disorders where HCT is the only proven cure, but challenging setting due to limited pre-conditioning options Multiple Potential FDA Filing Strategies SCID Fanconi Anemia
Slide 19: Briquilimab: Rapid and Deep Control of Chronic Spontaneous Urticaria
Briquilimab: Rapid and Deep Control of Chronic Spontaneous Urticaria Target Product Profile Briquilimab rapidly suppresses serum tryptase by week 1 and maintains suppression to week 8 with single dose (BEACON) Potency • Direct blockade of SCF binding site • High affinity c-Kit (Kd <5pM) and potency
Slide 20: KP701: Potentially Best-in-Class Anti-CD79BxCD32B
KP701 Potentially Best-in-Class Anti-CD79BxCD32B
Slide 21: KP701: Dual Engagement of CD79B and CD32B to Drive B-cell Tolerance
KP701: Dual Engagement of CD79B and CD32B to Drive B-cell Tolerance KP701 Mimics Endogenous B Cell Inhibition Pathway by Cross Linking CD79B (BCR) and CD32B • New approach to silence pathogenic B-cells/ B Cell Receptor (BCR) KP701 Driven Inhibition plasmablasts without deep depletion which leads to
Slide 22: KP-701: Potent Effects on B-cell Proliferation & Phagocytosis vs. Existing Programs
KP-701: Potent Effects on B-cell Proliferation & Phagocytosis vs. Existing Programs Superior potency observed compared to Obexilimiab, PRV3279 and Rituximab Rapid Phagocytosis of B cells at KP-701 Activity on SLE KP-701 Superior Activity in Low Concentrations vs. Existing Plasmablasts & IgG2 B-cell
Slide 23: KP-701: Unique Reductions in B Cells & Immunoglobulins in NHPs
KP-701: Unique Reductions in B Cells & Immunoglobulins (IgG & IgA) in NHPs Strong reductions in IgG, IgA and B cells Reduction of CD3-CD20+ IgG IgA in Peripheral Blood 110% 110% 110% 100% 100% 100% Normalized B cell Counts (% Baseline) 90% Normalized IgG (% Baseline) Normalized IgA (% Baseline) 80%
Slide 24: KP 701: Streamlined Phase 1a/b Strategy to Deliver Rapid Proof-of-Concept
KP 701: Streamlined Phase 1a/b Strategy to Deliver Rapid Proof-of-Concept Opportunity to Evaluate Safety, PK / PD & Preliminary Activity in Autoimmune Disease (AID) Designed to provide PK / PD, Phase 1a - SAD Phase 1b - MAD safety data & early signals on durability of KP-701 in AID DL 5 IV HVs DL 3
Slide 25: KP 701: Broad Therapeutic Potential for Large Patient Populations
KP 701: Broad Therapeutic Potential for Large Patient Populations Rapid proof-of-concept in rheumatology with potential expansion into other therapeutic areas Rheumatology Endocrinology Neurology Dermatology • Rheumatoid Arthritis • Graves’ Disease • Multiple Sclerosis • Immune • Lupus (SLE) • Thyro
Slide 26: Summary
Summary
Slide 27: $132M PIPE Expected to Fund the Combined Company Through Multiple Anticipated Clinical Catalysts
$132M PIPE Expected to Fund the Combined Company Through Multiple Anticipated Clinical Catalysts, Well Capitalized into 2H 2028 Multiple anticipated Phase 2 data readouts, two Phase 1 updates and potential Phase 3 start planned 2026E 2027E 2028E Q2 – Phase 2, Stage 1 updated data Q4 – Phase 2, Stage
Slide 28: Corporate Presentation September 2026
Corporate Presentation September 2026 28
Slide 29: Vensobafusp alfa: Potential Best-in-Class Profile Across Multiple Indications
Vensobafusp alfa: Potential Best-in-Class Profile Across Multiple Indications KP104 as potent as Ravulizumab in Unlike anti-C5 mABs, Target Product Profile inhibiting CP-triggered terminal vensobafusp also inhibits AP pathway complement activation* complement* C5 INHIBITION ASSAY LPS-BASED ELISA ASS
Jasper Therapeutics — Investor Presentation (September 2026) on 6ix